Alamar Biosciences, Inc. filed a Current Report on Form 8-K on November 3, 2026, disclosing the planned retirement of President Timothy "Tod" White effective December 31, 2026, and announcing the release of its financial results for the quarter ended September 30, 2026.

Key Highlights

  • President retirement: Timothy "Tod" White informed the company on October 30, 2026 that he will retire as President effective December 31, 2026, after more than five years of service.
  • Consulting agreement: White agreed to remain as a consultant from January 1, 2027 through June 30, 2027 to support an orderly transition and continuity of operations.
  • Q3 2026 results announced: The company issued a press release on November 3, 2026 announcing financial results for the quarter ended September 30, 2026.
  • CEO statement: Founder, CEO, and Chair Yuling Luo, Ph.D. credited White with helping build the foundation, managing multiple rounds of fundraising, and leaving the company "well-positioned for its next phase."
  • Emerging growth company: Alamar Biosciences is designated as an emerging growth company under applicable SEC rules, according to the filing.

Alamar Biosciences Discloses Presidential Transition and Q3 2026 Financial Results

According to the filing, Alamar Biosciences, Inc. (NASDAQ:ALMR) reported two separate disclosures in its November 3, 2026 Current Report. The first concerns a leadership change: Timothy "Tod" White notified the company on October 30, 2026 of his intent to retire from his role as President. His retirement is set to take effect on December 31, 2026, following what the filing describes as "more than five years of exemplary service."

The filing states that White has agreed to serve as a consultant to the company from January 1, 2027 through June 30, 2027, with the stated purpose of ensuring "an orderly transition and continuity of operations." No successor to the President role was named in the filing. CEO and Chair Yuling Luo, Ph.D. is quoted in the filing as saying White "helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase."

The filing also references the release of Alamar Biosciences' financial results for the quarter ended September 30, 2026, disclosed via a press release dated November 3, 2026, attached as Exhibit 99.1. The company notes that the information furnished under Item 2.02 and in Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, and is not subject to the liabilities of that section. The filing was signed by Justin McAnear, Chief Financial Officer, identified as Principal Financial Officer and Principal Accounting Officer.

What Was Disclosed

Alamar Biosciences disclosed the upcoming retirement of President Timothy "Tod" White on December 31, 2026, his consulting arrangement through June 30, 2027, and the release of third-quarter 2026 financial results via an attached press release.